Phase 1Completed
Bioavailability in Patient With Psoriasis: Metoject Prefilled Pen
Relative Bioavailability of Methotrexate (MTX) 50 mg/mL Administered Subcutaneously (SC) by a Disposable Autoinjector (Metoject® Prefilled Pen) Compared With Intramuscular (IM) Administration of the United States Reference Listed Drug Methotrexate Injection (USP 25 mg/mL [Hospira]) in Patients With Psoriasis
- Sponsor
- medac GmbH (Industry)
- Enrolment
- 35 enrolled
- Conditions
- Psoriasis
- Interventions
- Methotrexate
- Ages
- adults, older adults
- Registry
- NCT02097173
Full record on ClinicalTrials.gov
From the registry
This study is conducted to assess the relative bioavailability of MTX administered subcutaneously via a prefilled pen (50mg/mL) compared with MTX administered via IM injection (25mg/mL).
Primary outcomes
- To determine the relative bioavailability of MTX based on the parent compound MTX when administered by SC injection with a prefilled pen (50 mg/mL) as compared with IM administration (25 mg/mL)
History
Last registry update
Registered
Primary completion
Started